Allogeneic Stem Cell Transplantation Market Combating Chronic Diseases Hope for Blood Cancers

Allogeneic Stem Cell Transplantation Market worth $6.75 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Allogeneic Stem Cell Transplantation Market - (By Source (Bone Marrow, Peripheral Blood, Umbilical Cord Blood, Adipose Tissue, Dental Pulp, and Others), By Application

(Cancer, Autoimmune Diseases, Blood Disorders, Cardiac Disorders, Neurological Disorders, Diabetes, and Others), By End User (Hospitals, Research Institutes, Specialty Clinics, and Others), By Cell Type (Allogeneic MSCs, Allogeneic HSCs, and Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Allogeneic Stem Cell Transplantation Market is valued at US$ 3.66 Bn in 2022, and it is expected to reach US$ 6.75 Bn by 2031, with a CAGR of 7.21% during the forecast period of 2023-2031.


Get a free sample copy of the report: https://www.insightaceanalytic.com/request-sample/2241

Allogeneic Stem Cell Transplantation: A Growing Market
The most common use of stem cell transplantation is allogeneic transplantation. In this procedure, a patient receives healthy blood-forming stem cells from an unrelated donor with a similar genetic makeup or a related donor who is not an identical twin. The allogeneic stem cell transplantation market is experiencing rapid global growth due to several factors.

Factors Driving Market Growth
• Rise in Genetic Research: Advancements in genetic research for both diagnostic and therapeutic purposes are propelling the market forward.
• Increasing Chronic Illnesses: The growing prevalence of chronic diseases like cancer, autoimmune diseases, and cardiovascular issues is contributing to the market's expansion.

• Blood Malignancies and Allogeneic Stem Cell Therapy: The past decade has seen a rise in new cases of blood malignancies such as leukemia, lymphoma, and multiple myeloma. Allogeneic hematopoietic stem cell transplantation offers an effective treatment option for many of these drug-resistant and high-risk blood cancers.

• Growing Patient Population and Demand for New Therapies: According to the World Health Organization, cancer alone claimed ten million lives. The increasing number of patients suffering from various diseases, coupled with the growing demand for novel therapies, are key drivers of the market.

Challenges in Allogeneic Stem Cell Transplantation
Despite its life-saving potential, allogeneic stem cell transplantation faces challenges.

• Graft Rejection: The patient's immune system may recognize the new stem cells as foreign and reject them, preventing engraftment.

• Graft-versus-Host Disease (GVHD): In some cases, the donor's immune system might malfunction and attack the recipient's healthy tissues.

List Of Prominent Players In The Allogeneic Stem Cell Transplantation Market:

• Histogenics Corporation
• BrainStorm Cell Therapeutics Inc.
• Lineage Cell Therapeutics, Inc.
• Bluebird Bio
• Sanofi
• Talaris Therapeutics.
• Celgene Corporation
• Mesoblast Ltd.
• Pluristem Therapeutics Inc.
• MEDIPOST Co., Ltd.
• Takeda Pharmaceutical Company Limited
• Astellas Pharma Inc.
• Cellular Biomedicine Group, Inc.
• Biosolution Co., Ltd.
• StemCell Technologies Inc.
• Caladrius Biosciences, Inc.
• TiGenix N.V.
• ViaCord
• Vericel Corporation
• Regen Biopharma Inc.
• Gamida Cell Ltd.
• Others

Market Dynamics:

Drivers-
The growing demand for allogeneic stem cell transplantation is fueled by allogeneic uses of mesenchymal cells originating in mature tissues like bone marrow and fat and adipose tissue, which show great potential because of their immunomodulatory properties.

Beyond the scope of conventional hematopoietic stem cell transplantation, allogeneic MSC therapies are receiving growing attention for potential use in other areas of regenerative medicine. As market participants increase their capacity to harness the great clinical promise of allogeneic MSCs for additional applications, this represents a significant expansion.

Challenges:
The prime challenge is high cost, a shortage of competent individuals and a lack of norms and protocol because of lockdowns and isolation in emerging countries, which is predicted to slow the growth of the allogeneic stem cell transplantation market. Costs associated with setting up the infrastructure, manufacturing methods, quality control measures, and staff needed to perform an allogeneic stem cell transplant are high.

Logistical costs rise in proportion to the complexity of handling and transport. Affordability is significantly impacted by inadequate reimbursement and restricted insurance coverage in certain places. High therapy costs are a major factor holding back the market. Since COVID-19 has spread so quickly, many nations have instituted nationwide lockdowns.

Healthcare providers worldwide had trouble keeping their supply chains running smoothly for similar reasons. As COVID instances reduced, the severe limitations were lifted, increasing the frequency of hospital visits and allowing the patients to undergo therapy.

Regional Trends:
The North American allogeneic stem cell transplantation market is anticipated to record a major market share in revenue. It is projected to grow at a high CAGR in the near future due to technological advancements and affluence. Healthcare facilities in North America include general medical clinics and speciality facilities like transplant hospitals and cancer treatment facilities. All the latest equipment,

knowledge, and supplies required for a successful HSCT operation can be found at these centres. Besides, Europe had a considerable share in the market because of the high prevalence of myeloid malignancies, lymphoid malignancies, solid tumours, and non-malignant diseases in these regions. Demand for allogeneic and autologous stem cell transplants is rising in industrialized European countries.

Curious about this latest version of the report? Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/2241

Recent Developments:

• In September 2023, Mesoblast collaborated with the Blood & Marrow Transplant Clinical Trials Network (BMT CTN) to conduct a clinical trial examining the effectiveness of its drug, Ryoncil (remestemcel-L), in treating steroid-refractory acute graft versus host disease (SR-aGvHD). BMT CTN will undertake the trial to assess the efficacy of Ryoncil in patients aged 12 and above who have shown inadequate response to prior treatments such as corticosteroids and a second-line drug like ruxolitinib.

• In Jan 2020, Astellas and Adaptimmune formed a partnership to collaborate on the development and marketing of stem-cell derived allogeneic CAR-T and TCR T-cell treatments. The cooperation utilized Adaptimmune's ability in identifying and confirming targets to create T-cell Receptors (TCRs), chimeric antigen receptors (CARs), and HLA-independent TCRs that could recognize surface epitopes regardless of the HLA profile of the tumor cell.

Segmentation of Allogeneic Stem Cell Transplantation Market-
By Source
• Bone Marrow
• Peripheral Blood
• Umbilical Cord Blood
• Adipose Tissue
• Dental Pulp
• Others

By Cell Type
• Allogeneic MSCs (Allogenic Mesenchymal stem cells)
• Allogeneic HSCs (Allogeneic hematopoietic stem cells)
• Others

By Application
• Cancer
• Autoimmune Diseases
• Blood Disorders
• Cardiac Disorders
• Neurological Disorders
• Diabetes
• Others

By End User
• Hospitals
• Research Institutes
• Specialty Clinics
• Others

By Region-
North America-
• The US
• Canada
• Mexico

Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific

Latin America-
• Brazil
• Argentina
• Rest of Latin America

Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

For More Customization @ https://www.insightaceanalytic.com/report/allogeneic-stem-cell-transplantation-market/2241

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.
We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.
Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.